Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Aldeyra Therapeutics, Inc. (ALDX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 SC 13G Knoll Capital Management, LLC reports a 6.1% stake in Aldeyra Therapeutics Inc
08/24/2023 4 Walker Neal (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Exercised 9,604 options to buy @ $0.552, valued at $5.3k
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/05/2023 4 JOYCE MARTIN JOSEPH (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Granted 21,222 options to buy @ $8.39, valued at $178.1k
Granted 640 options to buy @ $8.39, valued at $5.4k
Granted 2,744 options to buy @ $8.39, valued at $23k
07/05/2023 4 Phillips Gary M. (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Granted 21,222 options to buy @ $8.39, valued at $178.1k
Granted 1,829 options to buy @ $8.39, valued at $15.3k
Granted 1,372 options to buy @ $8.39, valued at $11.5k
07/05/2023 4 Miller-Rich Nancy (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Granted 21,222 options to buy @ $8.39, valued at $178.1k
Granted 915 options to buy @ $8.39, valued at $7.7k
07/05/2023 4 Bronstein Ben (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Granted 21,222 options to buy @ $8.39, valued at $178.1k
Granted 1,372 options to buy @ $8.39, valued at $11.5k
Granted 1,464 options to buy @ $8.39, valued at $12.3k
07/05/2023 4 DOUGLAS RICHARD (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Granted 21,222 options to buy @ $8.39, valued at $178.1k
Granted 5,488 options to buy @ $8.39, valued at $46k
Granted 640 options to buy @ $8.39, valued at $5.4k
07/05/2023 4 Walker Neal (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Granted 21,222 options to buy @ $8.39, valued at $178.1k
Granted 915 options to buy @ $8.39, valued at $7.7k
07/03/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/29/2023 4 Bronstein Ben (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Exercised 9,604 options to buy @ $0.552, valued at $5.3k
06/29/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics, Inc. Presentation",
"Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa"
05/23/2023 ARS Form ARS - Annual Report to Security Holders:
05/23/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights"
03/02/2023 4 Machatha Stephen (Chief Development Officer) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Granted 220,258 options to buy @ $6.76, valued at $1.5M
03/02/2023 4 Greenberg Bruce (See Remarks) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Granted 110,028 options to buy @ $6.76, valued at $743.8k
03/02/2023 4 Brady Todd C (President and CEO) has filed a Form 4 on Aldeyra Therapeutics, Inc.
Txns: Granted 238,750 shares @ $0
Granted 250,000 options to buy @ $6.76, valued at $1.7M
03/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma"
02/14/2023 SC 13G/A PERCEPTIVE ADVISORS LLC reports a 19.4% stake in Aldeyra Therapeutics, Inc.
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease"
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/27/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Second Amendment to Loan and Security Agreement, and effective as of December 31, 2022, by and among Aldeyra Therapeutics, Inc., Helio Vision, LLC, the several banks and other financial institutions or entities from time to time parties thereto and Hercules Capital, Inc"
12/21/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/29/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy